Population pharmacokinetics of carbamazepine in elderly patients

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 176-181

  Punyawudho, Baralee ^a,b   Ramsay, Eugene R ^c   Brundage, Richard C ^a   MacIas, Flavia M ^c   Collins, Joseph F ^d   Birnbaum, Angela K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

aged; anticonvulsants; carbamazepine; pharmacokinetics

Indexed keywords

CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADULT; AGED; ARTICLE; BODY SIZE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; ELDERLY CARE; EPILEPSY; FEMALE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; BODY WEIGHT; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PHENYTOIN; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 84858700349     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824d6a4e     Document Type: Article

References (30)

1. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27-47. (Pubitemid 350243365)
2. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334: 168-175.
3. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia. 1991;32:429-445.
4. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64:1868-1873. (Pubitemid 40800699)
5. Savica R, Beghi E, Mazzaglia G, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol. 2007;14:1317-1321. (Pubitemid 350135294)
6. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med. 1994;3:589-598.
7. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998;23:247-255. (Pubitemid 28532449)
8. Salem SA, Rajjayabun P, Shepherd AM, et al. Reduced induction of drug metabolism in the elderly. Age Ageing. 1978;7:68-73.
9. Twum-Barima Y, Finnigan T, Habash AI, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol. 1984;17:595-597. (Pubitemid 14057470)
10. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia. 2003;44:923-929. (Pubitemid 36842182)
11. Birnbaum AK, Conway JM, Hardie NA, et al. Carbamazepine dose-concentration relationship in elderly nursing home residents. Epilepsy Res. 2007;77:31-35. (Pubitemid 47588844)
12. Beal SL, Sheiner LB. NONMEM User's Guide. San Francisco: University of California, San Francisco, NONMEM Project Group; 1994.
13. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64. (Pubitemid 29049052)
14. Wahlby U, Bouw MR, Jonsson EN, et al. Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn. 2002;29:251-269. (Pubitemid 35333142)
15. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231-252. (Pubitemid 32643366)
16. Efron B, Gong G. A leisurely look at the bootstrap, the jacknife, and cross-validation. Am Stat. 1983;37:36-48.
17. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623. (Pubitemid 36613120)
18. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495. (Pubitemid 27265649)
19. Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet. 1978;3:128-143.
20. Punyawudho B, Cloyd JC, Leppik IE, et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet. 2009;48:313-320.
21. Bondareva IB, Jelliffe RW, Gusev EI, et al. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. J Clin Pharm Ther. 2006;31:211-221. (Pubitemid 43873543)
22. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy. 1998;18: 273-281. (Pubitemid 28145143)
23. Jiao Z, Shi XJ, Zhao ZG, et al. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther. 2004;29:247-256. (Pubitemid 38901536)
24. Reith DM, Hooper WD, Parke J, et al. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults. J Pharmacokinet Pharmacodyn. 2001;28:79-92.
25. Hockings N, Pall A, Moody J, et al. The effects of age on carbamazepine pharmacokinetics and adverse effects. Br J Clin Pharmacol. 1986;22: 725-728. (Pubitemid 17199015)
26. Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand. 1973;49:543-546.
27. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9: 298-303. (Pubitemid 17149392)
28. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32:703-718. (Pubitemid 41781922)
29. al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990;18:347-360. (Pubitemid 20327531)
30. Sun H, Ette EI, Ludden TM. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data. J Pharmacokinet Biopharm. 1996;24:637-650.